Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2026)
Entrada Therapeutics' (TRDA) quarterly EBITDA Margin came in at 4834.63% in Q1 2026, down 472864.0% year-on-year from N/an in Q1 2025, and down 48.79% quarter-over-quarter from 3249.27% in Q4 2025.
Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 4834.63% for Q1 2026.
- On a quarterly basis, EBITDA Margin fell 472864.0% year-over-year to 4834.63% in Q1 2026; TTM through Mar 2026 was 3109.29%, a 311167.0% decrease from a year earlier, with the FY2025 full-year figure at 621.13%, down 64344.0% from the prior year.
- EBITDA Margin slipped to 4834.63% in Q1 2026 per TRDA's latest filing, from 3249.27% in the prior quarter.
- Across five years, EBITDA Margin topped out at 56.42% in Q2 2024 and bottomed at 4834.63% in Q1 2026.
- The 4-year median for EBITDA Margin is 89.7% (2023), against an average of 1046.97%.
- Across the five-year window, EBITDA Margin soared 14612 bps in 2024 and plunged 472864 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 11.72% in 2023, then sank by 234 bps to 15.69% in 2024, then sank by 20612 bps to 3249.27% in 2025, then plunged by 49 bps to 4834.63% in 2026.
- Per Business Quant, the three latest TRDA EBITDA Margin figures stand at 4834.63% (Q1 2026), 3249.27% (Q4 2025), and 2915.18% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | -4,834.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,834.63% |
| Dec 31, 2025 | -3,249.27% |
| Sep 30, 2025 | -2,915.18% |
| Jun 30, 2025 | -2,402.51% |
| Mar 31, 2025 | -105.99% |
| Dec 31, 2024 | -15.69% |
| Sep 30, 2024 | -110.67% |
| Jun 30, 2024 | 56.42% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | 11.72% |
| Sep 30, 2023 | 32.04% |
| Jun 30, 2023 | -89.70% |
| Mar 31, 2023 | -22.88% |